Open AccessAnalysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed
Author(s) -
Mark S. Butler,
Valeria Gigante,
Hatim Sati,
Sarah Paulin,
Laila Al-Sulaiman,
John H. Rex,
Prabhavathi Fernandes,
Cesar A. Arias,
Mical Paul,
Guy E. Thwaites,
Lloyd Czaplewski,
Richard A. Alm,
Christian Lienhardt,
Melvin Spigelman,
Lynn L. Silver,
Norio Ohmagari,
Roman Kozlov,
Stephan Harbarth,
Peter Beyer
Publication year - 2022
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01991-21
Subject(s) - medicine , antibacterial agent , antibiotics , antibacterial activity , clinical trial , intensive care medicine , antibacterial peptide , cephalosporin , pharmacology , phases of clinical research , clinical microbiology , clinical efficacy , drug development , microbiology and biotechnology , pathogenic bacteria , clinical research
There is an urgent global need for new strategies and drugs to control and treat multidrug-resistant bacterial infections. In 2017, the World Health Organization (WHO) released a list of 12 antibiotic-resistant priority pathogens and began to critically analyze the antibacterial clinical pipeline. This review analyzes “traditional” and “nontraditional” antibacterial agents and modulators in clinical development current on 30 June 2021 with activity against the WHO priority pathogens mycobacteria andClostridioides difficile .
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom